花园生物股价波动显著，机构评级中性目标价22元

Group 1 - The stock price of Huayuan Bio (300401) experienced significant fluctuations in the past week, with a peak increase of 5.98% on February 6, closing at 19.15 yuan, and a total market value of 95.65 billion yuan as of February 12 [1] - The stock showed a trading range of 12.45% and a high turnover rate, indicating active trading, with a net outflow of 39.57 million yuan from institutional investors and a net inflow of 39.57 million yuan from retail investors on February 12 [1] Group 2 - Huayuan Bio is recognized as a leader in the vitamin segment and has gained market attention as a hot stock in the chemical sector, with significant holdings by Southern Fund's CSI 1000 ETF, which owns 347.85 thousand shares (0.65% of circulating shares) but reduced its holdings by 48.4 thousand shares in the third quarter [2] - The chemical sector, particularly phosphates and vitamins, has been driven by policy and demand, with Huayuan Bio being highlighted for its vitamin D3 supply chain [2] Group 3 - Institutional ratings for Huayuan Bio are generally neutral, with a target price of 22.00 yuan, indicating a potential upside of 21.48% from the latest price [3] - The forecast for net profit growth is modest, with a projected increase of 0.18% for 2025 and a more substantial growth of 40.35% expected in 2026, while the current price-to-earnings ratio (TTM) stands at 31.69 [3] - The proportion of institutional holdings is relatively low at 0.11%, and the frequency of institutional research is average [3]